Vaxxas
Commercializing novel technology that dramatically enhances the performance of existing and next-generation vaccines. Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
€84—125m (Dealroom.co estimates Dec 2022.)
Brisbane Queensland (HQ), Sydney New South Wales (founding location)
Authorizing premium user...